A comparative economic analysis of simvastatin versus atorvastatin: results of the Surrogate Marker Cost-Efficacy (SMaC) study.
Arikian
S
S
D000924:Anticholesteremic Agents / Q000191:economics* / Q000627:therapeutic use*; D000069059:Atorvastatin; D003365:Costs and Cost Analysis; D006538:Heptanoic Acids / Q000191:economics* / Q000627:therapeutic use*; D006801:Humans; D011758:Pyrroles / Q000191:economics* / Q000627:therapeutic use*; D019821:Simvastatin / Q000191:economics* / Q000627:therapeutic use*
D000924:Anticholesteremic Agents; D006538:Heptanoic Acids; D011758:Pyrroles; D000069059:Atorvastatin; D019821:Simvastatin